Home » GSK and Genmab’s Ofatumumab Wins FDA Breakthrough Therapy Designation
GSK and Genmab’s Ofatumumab Wins FDA Breakthrough Therapy Designation
The FDA has approved GSK and Genmab’a Arzerra (ofatumumab) in combination with chlorambucil as a breakthrough therapy for chronic lymphocytic leukemia.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May